Intraperitoneal chemotherapy: Phase III trials

David S. Alberts, Mary C. Clouser

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

It is well documented that epithelial-type ovarian cancer growth remains within the intraperitoneal (IP) space for the majority of its natural history, making even advanced disease (e.g., stage III) amenable to regional therapy. The concept of IP delivery of chemotherapy goes back more than 40 years to the bioengineer, Robert Dedrick, whose research group at the National Institutes of Health developed animal and mathematical models to describe the disposition of cytotoxic agents administered directly into the IP space [1]. Most notably, his preclinical research led to the belly bath as a way of delivering cell-cycle specific agents by continuous 4 h infusions, leading to phase I/II clinical trials of IP 5-fluorouracil and methotrexate in patients with advanced ovarian cancer at the National Cancer Institute (NCI) [2, 3].

Original languageEnglish (US)
Title of host publicationIntraperitoneal Therapy for Ovarian Cancer
PublisherSpringer Berlin Heidelberg
Pages37-50
Number of pages14
ISBN (Print)9783642121296
DOIs
StatePublished - Dec 1 2010

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Intraperitoneal chemotherapy: Phase III trials'. Together they form a unique fingerprint.

  • Cite this

    Alberts, D. S., & Clouser, M. C. (2010). Intraperitoneal chemotherapy: Phase III trials. In Intraperitoneal Therapy for Ovarian Cancer (pp. 37-50). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-642-12130-2_4